In contrast to robust activity observed in the use of single agent checkpoint inhibitors targeting CTLA-4 or PD-1 in many other cancers, activity in pancreatic cancer has been minimal [14, 21], likely resulting from the immunologic inert microenvironment and limited T cell infiltration of the tumor parenchyma [20]. Here, CTLA4 is linked to pancreatic neoplasm.